Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2009

01-04-2009 | Original Article

The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations

Authors: David H. Au, MD, MS, Christopher L. Bryson, MD, MPH, Jason W. Chien, MD, MS, Haili Sun, PhD, Edmunds M. Udris, MPH, Laura E. Evans, MD, MS, Katharine A. Bradley, MD, MPH

Published in: Journal of General Internal Medicine | Issue 4/2009

Login to get access

Abstract

BACKGROUND

Smoking cessation has been demonstrated to reduce the rate of loss of lung function and mortality among patients with mild to moderate chronic obstructive pulmonary disease (COPD). There is a paucity of evidence about the effects of smoking cessation on the risk of COPD exacerbations.

OBJECTIVE

We sought to examine whether smoking status and the duration of abstinence from tobacco smoke is associated with a decreased risk of COPD exacerbations.

DESIGN

We assessed current smoking status and duration of smoking abstinence by self-report. Our primary outcome was either an inpatient or outpatient COPD exacerbation. We used Cox regression to estimate the risk of COPD exacerbation associated with smoking status and duration of smoking cessation.

PARTICIPANTS

We performed a cohort study of 23,971 veterans who were current and past smokers and had been seen in one of seven Department of Veterans Affairs (VA) primary care clinics throughout the US.

MEASUREMENTS AND MAIN RESULTS

In comparison to current smokers, ex-smokers had a significantly reduced risk of COPD exacerbation after adjusting for age, comorbidity, markers of COPD severity and socio-economic status (adjusted HR 0.78, 95% CI 0.75–0.87). The magnitude of the reduced risk was dependent on the duration of smoking abstinence (adjusted HR: quit <1 year, 1.04; 95% CI 0.87–1.26; 1–5 years 0.93, 95% CI 0.79–1.08; 5–10 years 0.84, 95% CI 0.70–1.00; ≥10 years 0.65, 95% CI 0.58–0.74; linear trend <0.001).

CONCLUSIONS

Smoking cessation is associated with a reduced risk of COPD exacerbations, and the described reduction is dependent upon the duration of abstinence.
Literature
1.
go back to reference Data Fact Sheet: Chronic Obstructive Pulmonary Disease, National Heart Blood and Lung Institiute. NIH Publication Number 2003;30–5229. Data Fact Sheet: Chronic Obstructive Pulmonary Disease, National Heart Blood and Lung Institiute. NIH Publication Number 2003;30–5229.
2.
go back to reference Calverley PM. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:121–4.PubMedCrossRef Calverley PM. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:121–4.PubMedCrossRef
3.
go back to reference Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999;106:410–6.PubMedCrossRef Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999;106:410–6.PubMedCrossRef
4.
go back to reference Bolliger CT, Zellweger JP, Danielsson T, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res. 2002;4:433–9.PubMedCrossRef Bolliger CT, Zellweger JP, Danielsson T, et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res. 2002;4:433–9.PubMedCrossRef
5.
go back to reference Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–9.PubMed Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–9.PubMed
6.
go back to reference Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:279–87.PubMed Faulkner MA, Lenz TL, Stading JA. Cost-effectiveness of smoking cessation and the implications for COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:279–87.PubMed
7.
go back to reference Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51–61.PubMedCrossRef Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin. 2008;24:51–61.PubMedCrossRef
8.
go back to reference Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health. 2005;33:343–52.PubMedCrossRef Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children. Scand J Public Health. 2005;33:343–52.PubMedCrossRef
9.
10.
go back to reference Fan VS, Au D, Heagerty P, Deyo RA, McDonell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnoses and health. J Clin Epidemiol. 2002;55:371–80.PubMedCrossRef Fan VS, Au D, Heagerty P, Deyo RA, McDonell MB, Fihn SD. Validation of case-mix measures derived from self-reports of diagnoses and health. J Clin Epidemiol. 2002;55:371–80.PubMedCrossRef
11.
go back to reference The Health Consequences of Smoking: a Report of the Surgeon General. Washington DC: Department of Health and Human Services, Centers for Disease Control and Prevention. 2004;42–61. The Health Consequences of Smoking: a Report of the Surgeon General. Washington DC: Department of Health and Human Services, Centers for Disease Control and Prevention. 2004;42–61.
13.
go back to reference Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.PubMedCrossRef Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet. 2007;370:2044–53.PubMedCrossRef
14.
go back to reference Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79:971–9.PubMed Ait-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79:971–9.PubMed
15.
go back to reference Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62(Suppl 2):1–9.PubMedCrossRef Fagerstrom K. The epidemiology of smoking: health consequences and benefits of cessation. Drugs. 2002;62(Suppl 2):1–9.PubMedCrossRef
16.
go back to reference Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Jama. 1994;272:1497–505.PubMedCrossRef Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Jama. 1994;272:1497–505.PubMedCrossRef
17.
go back to reference Anthonisen NR. Long-term oxygen therapy. Ann Intern Med. 1983;99:519–27.PubMed Anthonisen NR. Long-term oxygen therapy. Ann Intern Med. 1983;99:519–27.PubMed
18.
go back to reference American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. New York: American Thoracic Society. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD [Internet]. New York: American Thoracic Society.
19.
go back to reference Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166:105–10.PubMedCrossRef Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med. 2002;166:105–10.PubMedCrossRef
20.
go back to reference Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822–6.PubMed Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822–6.PubMed
21.
go back to reference Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250–5.PubMedCrossRef Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250–5.PubMedCrossRef
22.
go back to reference Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–20.PubMedCrossRef Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–20.PubMedCrossRef
23.
go back to reference Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004.PubMedCrossRef Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128:1995–2004.PubMedCrossRef
24.
go back to reference Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6:151.PubMedCrossRef Mercer PF, Shute JK, Bhowmik A, Donaldson GC, Wedzicha JA, Warner JA. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res. 2005;6:151.PubMedCrossRef
25.
go back to reference Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147:639–53.PubMed Wilt TJ, Niewoehner D, MacDonald R, Kane RL. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147:639–53.PubMed
26.
go back to reference Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.PubMedCrossRef Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.PubMedCrossRef
27.
go back to reference Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26:835–45.PubMedCrossRef Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J. 2005;26:835–45.PubMedCrossRef
28.
go back to reference Cummings KM, Giovino G, Jaen CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav. 1985;10:373–81.PubMedCrossRef Cummings KM, Giovino G, Jaen CR, Emrich LJ. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav. 1985;10:373–81.PubMedCrossRef
29.
go back to reference Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest. 1998;113:883–9.PubMedCrossRef Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest. 1998;113:883–9.PubMedCrossRef
30.
go back to reference Yamashita S, Yamaguchi H, Sakaguchi M, Yamamoto S, Aoki K, Shiga Y, Hisajima Y. Effect of smoking on intraoperative sputum and postoperative pulmonary complication in minor surgical patients. Respir Med. 2004;98:760–6.PubMedCrossRef Yamashita S, Yamaguchi H, Sakaguchi M, Yamamoto S, Aoki K, Shiga Y, Hisajima Y. Effect of smoking on intraoperative sputum and postoperative pulmonary complication in minor surgical patients. Respir Med. 2004;98:760–6.PubMedCrossRef
31.
go back to reference Verra F, Escudier E, Lebargy F, Bernaudin JF, De Cremoux H, Bignon J. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med. 1995;151:630–4.PubMed Verra F, Escudier E, Lebargy F, Bernaudin JF, De Cremoux H, Bignon J. Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers. Am J Respir Crit Care Med. 1995;151:630–4.PubMed
32.
go back to reference Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20–8.PubMedCrossRef Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20–8.PubMedCrossRef
33.
go back to reference Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007;9:21–32.PubMedCrossRef Wilt TJ, Niewoehner D, Kane RL, MacDonald R, Joseph AM. Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. Nicotine Tob Res. 2007;9:21–32.PubMedCrossRef
34.
go back to reference Boyd NR, Windsor RA, Perkins LL, Lowe JB. Quality of measurement of smoking status by self-report and saliva cotinine among pregnant women. Matern Child Health J. 1998;2:77–83.PubMedCrossRef Boyd NR, Windsor RA, Perkins LL, Lowe JB. Quality of measurement of smoking status by self-report and saliva cotinine among pregnant women. Matern Child Health J. 1998;2:77–83.PubMedCrossRef
35.
go back to reference Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-xanalysis. Tob Control. 2006;15:280–5.PubMedCrossRef Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-xanalysis. Tob Control. 2006;15:280–5.PubMedCrossRef
36.
go back to reference Stxate Medicaid coverage for tobacco-dependence treatments-United States. 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1194–7. Stxate Medicaid coverage for tobacco-dependence treatments-United States. 2005. MMWR Morb Mortal Wkly Rep. 2006;55:1194–7.
37.
go back to reference Curry SJ, Keller PA, Orleans CT, Fiore MC. The Role of Health Care Systems in Increased Tobacco Cessation. Annu Rev Public Health 2008. Curry SJ, Keller PA, Orleans CT, Fiore MC. The Role of Health Care Systems in Increased Tobacco Cessation. Annu Rev Public Health 2008.
Metadata
Title
The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations
Authors
David H. Au, MD, MS
Christopher L. Bryson, MD, MPH
Jason W. Chien, MD, MS
Haili Sun, PhD
Edmunds M. Udris, MPH
Laura E. Evans, MD, MS
Katharine A. Bradley, MD, MPH
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 4/2009
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-009-0907-y

Other articles of this Issue 4/2009

Journal of General Internal Medicine 4/2009 Go to the issue

Reflection

BAIT

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.